Acquired Agranulocytosis
Acquired Agranulocytosis is a VA-ratable condition under diagnostic code 7702 in the Blood & Lymphatic System category. Maximum rating: 100%.
Rating Criteria
| Rating | Criteria |
|---|---|
| 100% | Requiring bone marrow transplant; **OR** infections recurring, on average, at least once every 6 weeks per 12-month period. |
| 60% | Requiring intermittent myeloid growth factors (granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) or continuous immunosuppressive therapy such as cyclosporine to maintain (ANC) greater than 500/microliter (µl) but less than 1000/µl; **OR** infections recurring, on average, at least once every 3 months per per 12-month period. |
| 30% | Requiring intermittent myeloid growth factors to maintain ANC greater than 1000/µl; **OR** infections recurring, on average, at least once per 12-month period but less than once every 3 months per 12-month period. |
| 10% | Requiring continuous medication (e.g., antibiotics) for control; **OR** requiring intermittent use of a myeloid growth factor to maintain absolute neutrophil count (ANC) greater than or equal to 1500/µl. |
Filing Tips
Pro Tip: The VA won't connect the dots for you. That's your job. Build the paper trail before you file.
Gather medical evidence showing a current diagnosis of this condition.
Document in-service events, injuries, or exposures that caused or aggravated this condition.
Consider a nexus letter from a medical professional linking your condition to service.
Review the rating criteria for DC 7702 to understand what symptoms warrant higher ratings.